36 results on '"Gilloteau, Isabelle"'
Search Results
2. Patient-reported outcomes in capmatinib-treated patients with METex14-mutated advanced NSCLC: Results from the GEOMETRY mono-1 study
3. The effect of secukinumab on patient-reported outcomes in patients with active psoriatic arthritis in a randomised phase 3 trial
4. Secukinumab and Sustained Reduction in Fatigue in Patients With Ankylosing Spondylitis: Long‐Term Results of Two Phase III Randomized Controlled Trials
5. Secukinumab is Superior to Ustekinumab in Clearing Skin in Patients with Moderate to Severe Plaque Psoriasis (16-Week CLARITY Results)
6. Disease Burden and Treatment Patterns of Psoriasis in Russia: A Real-World Patient and Dermatologist Survey
7. Caring for relatives with lung cancer in Europe: an evaluation of caregivers' experience
8. Understanding the patient experience and treatment benefits in patients with non–small‐cell lung cancer with brain metastasis.
9. Quantifying the burden of informal caregiving for patients with cancer in Europe
10. Patient-reported outcomes in capmatinib-treated patients with METex14-mutated advanced NSCLC: Results from the phase II GEOMETRY mono-1 study.
11. Exploring determinants of psoriasis patients' treatment choices: a discrete-choice experiment study in the United States and Germany.
12. Exploring determinants of psoriasis patients’ treatment choices: a discrete-choice experiment study in the United States and Germany
13. Secukinumab demonstrates sustained efficacy in clearing skin and improving patient-reported outcomes in patients with moderate-to-severe psoriasis through 2 years of treatment: Results from the CLEAR study
14. Secukinumab and Sustained Reduction in Fatigue in Patients With Ankylosing Spondylitis: Long‐TermResults of Two Phase IIIRandomized Controlled Trials
15. Secukinumab demonstrates sustained efficacy in clearing skin and improving patient-reported outcomes in patients with moderateto-severe psoriasis through 2 years of treatment: Results from the CLEAR study
16. SLEEPI-i Study, a Multicountry Survey: Similarities and Differences in Socio-Demographic Characteristics and Quality of Life in Chronic Insomniacs: 513.
17. Evaluating the cost-effectiveness of secukinumab in moderate to severe psoriasis: a Japanese perspective
18. FRI0388 SECUKINUMAB IMPROVES HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH ANKYLOSING SPONDYLITIS, IRRESPECTIVE OF TIME SINCE FIRST DIAGNOSIS: POOLED RESULTS FROM THE SECUKINUMAB PHASE 3 TRIAL PROGRAM
19. Patient-reported outcomes are important elements of psoriasis treatment decision making: A discrete choice experiment survey of dermatologists in the United States
20. AB0782 SECUKINUMAB PROVIDES IMPROVEMENTS IN HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH PSORIATIC ARTHRITIS, REGARDLESS OF THE TIME SINCE DIAGNOSIS: POOLED RESULTS FROM THE SECUKINUMAB PHASE 3 TRIAL PROGRAM
21. Dose increase beyond labelled dose of biologics is associated with incremental pharmacy costs: results from a real-world study in the UK
22. Evaluating the cost-effectiveness of secukinumab in moderate-to-severe psoriasis: a Japanese perspective
23. Higher Psoriasis Skin Clearance Is Associated with Lower Annual Indirect Costs in the United States: A Post Hoc Analysis from the CLEAR Study
24. Effect of secukinumab on quality of life and psoriasis-related symptoms: A comparative analysis versus ustekinumab from the CLEAR 52-week study
25. Economic burden of comorbidities in psoriasis patients in the United States: results from a retrospective U.S. database
26. Secukinumab sustains early patient-reported outcome benefits through 1 year: Results from 2 phase III randomized placebo-controlled clinical trials comparing secukinumab with etanercept
27. Psoriasis patients with psoriasis Area and Severity Index (PASI) 90 response achieve greater health-related quality-of-life improvements than those with PASI 75–89 response: results from two phase 3 studies of secukinumab
28. Dose increase beyond labelled dose of biologics is associated with incremental pharmacy costs: results from a real-world study in the UK.
29. Evaluating the cost-effectiveness of secukinumab in moderate-to-severe psoriasis: a Japanese perspective.
30. Effect of nivolumab (NIVO) on quality of life (QoL) in patients (pts) with treatment-naïve advanced melanoma (MEL): Results of a phase III study (CheckMate 066).
31. Effect of nivolumab (NIVO) in combination with ipilimumab (IPI) versus IPI alone on quality of life (QoL) in patients (pts) with treatment-naïve advanced melanoma (MEL): Results of a phase II study (CheckMate 069).
32. Sleep Problems in Patients with Rheumatoid Arthritis
33. Sleep Problems in Patients with Rheumatoid Arthritis.
34. Secukinumab Provides Rapid Relief From Itching and Pain in Patients with Moderate-to-Severe Psoriasis: Patient Symptom Diary Data from Two Phase 3, Randomized, Placebo-controlled Clinical Trials.
35. Measurement of adherence to BCR-ABL inhibitor therapy in chronic myeloid leukemia: current situation and future challenges.
36. Abatacept or infliximab for patients with rheumatoid arthritis and inadequate response to methotrexate: an Italian trial-based and real-life cost-consequence analysis.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.